1 study on Ghs r 1a mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**NN703 demonstrates that oral GH secretagogue therapy is pharmacologically viable**, with a 30% bioavailability and 4.1-hour half-life that are compatible with once-daily dosing — a profile ipamorelin itself cannot a…